+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Human Organoids Market: Global Forecast to 2031

  • PDF Icon

    Report

  • 405 Pages
  • November 2026
  • Region: Global
  • Markets and Markets
  • ID: 5229105
The global human organoids market is projected to reach USD 0.90 billion by 2031 from USD 0.29 billion in 2026, at a CAGR of 25.6%. The global human organoids market is expected to expand during the forecast period as pharmaceutical and research organizations adopt models that capture key features of human tissue biology. The study covers finished organoid models and model development and organoid-based testing services for medical and pharmaceutical applications. Separately sold media, reagents, consumables, and instruments are excluded, as are cosmetic, veterinary, food, agricultural, and environmental uses. The FDA’s April 2025 roadmap supports evaluating validated non-animal methods, including organoid toxicity testing. Demand for disease-specific models and scalable screening creates opportunities for suppliers. Costs, specialized expertise, batch variability, and incomplete tissue maturation can limit adoption and require careful validation.

Ready-to-use and customizable organoid models support access to human-relevant research systems

Based on offerings, the market is segmented into organoid models and services. The models segment covers ready-to-use and customizable organoids supplied as finished products. Services include model development and organoid model-based testing. Researchers purchasing models can conduct experiments in their own laboratories, while outsourced services provide specialized development and screening capabilities. Molecular Devices (US), a Danaher company, supplies assay-ready organoids and custom expansion services. HUB Organoids (Netherlands), part of Merck KGaA (Germany), provides custom model development and drug screening. Model quality, donor characteristics, and assay suitability influence purchasing decisions across pharmaceutical companies, research institutes, and CROs/CRDMOs.

Intestinal and colorectal organoid models address gastrointestinal research and oncology screening needs

Based on model type, the study covers liver, intestinal & colorectal, kidney, pancreatic, lung, heart, and other organoid models. Other models include brain, retinal, breast, and skin organoids. Intestinal and colorectal models enable researchers to investigate epithelial function, disease mechanisms, and drug response in patient-relevant systems. Molecular Devices (US) offers assay-ready colorectal cancer and intestinal organoid lines, illustrating commercial access to finished models. Kidney organoids also support renal disease research, as demonstrated by Evotec’s (Germany) iPSC-derived kidney organoid capabilities. Demand across model types depends on tissue function, disease coverage, and suitability for the intended experimental endpoints.

Organoid research services are expanding opportunities in Asia Pacific during the forecast period

The regional scope comprises North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Asia Pacific offers opportunities as providers expand human organoid-based drug discovery services. Samsung Biologics (South Korea) launched Samsung Organoids in June 2025, extending its services into preclinical research through patient-derived tumor organoid screening. WuXi AppTec (China), through WuXi Biology, develops xenograft-derived organoid models for in vitro oncology screening. These capabilities support demand for disease-relevant models and outsourced therapeutic evaluation. Growth across the region will depend on research investment, access to patient material, model reproducibility, and validation of organoid methods for specific applications.

Primary research respondent categories for the human organoids study include:

  • By Respondent: Supply-side providers of organoid models and services; demand-side users in pharmaceutical, biotechnology, and biomedical research organizations
  • By Company Type: Diversified life science companies, CROs/CRDMOs, specialist organoid developers, and startups/SMEs
  • By Designation: CXOs and directors, research and business managers, scientists, and other technical specialists
  • By Region: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa

List of Companies Covered in the Study

  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Merck KGaA
  • Eurofins Scientific
  • WuXi AppTec
  • Charles River Laboratories
  • Bruker Corporation
  • Pharmaron
  • Evotec
  • ACROBiosystems
  • Samsung Biologics
  • Other Players

Research Coverage

This report categorizes the human organoids market by offering, model type, culture type, source, disease area, application, end user, and region. Model and service end users are assessed separately. The study covers historical years 2023-2024, base year 2025, and forecasts for 2026-2031. It examines drivers, restraints, opportunities, challenges, pricing, funding, technological advances, AI applications, and regulatory developments. Competitive coverage includes company profiles, revenue and market share analysis, company evaluation matrices, offering footprints, and strategic developments. Market revenue is restricted to finished human organoid models and model development and testing services. General culture supplies and instruments are excluded from the market estimates.

Key Benefits of Buying the Report

The report helps established suppliers and new entrants assess revenue opportunities across finished organoid models and research services. It supports decisions on model portfolios, therapeutic focus, customer groups, and geographic expansion. Analysis of supplier capabilities, buying criteria, and adoption barriers helps stakeholders develop market entry and partnership strategies. The study also examines how standardization, scalable production, and validated testing methods may affect demand and competitive positioning.

The report provides insights into the following pointers:

  • Analysis of key drivers (demand for human-relevant drug screening, patient-derived disease models, and validated alternatives to animal testing), restraints (model development costs and specialized expertise), opportunities (scalable organoid supply, personalized medicine research, and AI-assisted model standardization), and challenges (batch variability, limited tissue maturation, and cross-laboratory reproducibility) affecting the human organoids market.
  • Product Development/Innovation: Insights into finished organoid models, model development and testing services, automation, and AI-assisted organoid workflows.
  • Market Development: Assessment of opportunities for human organoid models and services across six regions and the countries included in the study scope.
  • Market Diversification: Analysis of emerging disease models, research applications, underserved customer needs, funding, and geographic expansion opportunities.
  • Competitive Assessment: Assessment of market positioning, growth strategies, and organoid offerings of companies, including Merck KGaA (Germany), Danaher Corporation (US), Samsung Biologics (South Korea), WuXi AppTec (China), and Evotec (Germany).

Table of Contents

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS SEGMENTATION & REGIONS COVERED
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 MARKET HIGHLIGHTS & KEY INSIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS IN HUMAN ORGANOIDS MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 HUMAN ORGANOIDS MARKET OVERVIEW
3.2 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY PRODUCT TYPE AND COUNTRY
3.3 HUMAN ORGANOIDS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
3.4 HUMAN ORGANOIDS MODELS MARKET SHARE, BY END USER, 2026 VS 2031 (%)
3.5 HUMAN ORGANOIDS SERVICES MARKET SHARE, BY END USER, 2026 VS 2031 (%)
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Growing demand for human-relevant drug testing and non-animal evidence
4.2.1.2 Expansion of standardized organoid supply and outsourced testing capacity
4.2.2 RESTRAINTS
4.2.2.1 High model establishment costs and lengthy experimental turnaround
4.2.3 OPPORTUNITIES
4.2.3.1 Patient-linked organoid screening for functional precision oncology
4.2.3.2 Expansion into immune and non-oncology organoid applications
4.2.4 CHALLENGES
4.2.4.1 Reproducibility and fit-for-purpose predictive validation
4.3 UNMET NEEDS AND WHITE SPACES
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 THREAT OF SUBSTITUTES
5.1.3 BARGAINING POWER OF BUYERS
5.1.4 BARGAINING POWER OF SUPPLIERS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC OUTLOOK
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.2.3 TRENDS IN THE GLOBAL HUMAN ORGANOIDS MARKET
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
5.4.1 LIST OF KEY HUMAN ORGANOID MODEL AND SERVICE PROVIDERS
5.4.2 PRODUCTION SITES AND CAPABILITY DEVELOPMENTS OF KEY ORGANOID PROVIDERS
5.5 PRICING ANALYSIS
5.5.1 AVERAGE SELLING PRICE, BY PRODUC/ SERVICE
5.6 KEY CONFERENCES & EVENTS, 2026-2027
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.8 INVESTMENT & FUNDING SCENARIO
5.9 IMPACT OF 2025 US TARIFFS - GLOBAL HUMAN ORGANOIDS MARKET
5.9.1 INTRODUCTION
5.9.2 PRICE IMPACT ANALYSIS
5.9.3 IMPACT ON REGIONS
5.9.3.1 North America
5.9.3.2 Europe
5.9.3.3 Asia Pacific
5.9.4 IMPACT ON END-USE INDUSTRIES
5.9.4.1 Pharmaceutical and Biotechnology Companies
5.9.4.2 Academic and Research Institutes
5.9.4.3 CROs/CRDMOs and Other Research End Users
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 KEY EMERGING TECHNOLOGIES
6.1.1 AI-ENABLED AND DIGITAL AUTOMATED AND HIGH-THROUGHPUT ORGANOID PLATFORMS
6.2 ADJACENT TECHNOLOGIES
6.2.1 ORGAN-ON-CHIP/MICROPHYSIOLOGICAL SYSTEMS
6.2.2 ADVANCED SPHEROID & 3D MICROTISSUE MODELS
6.3 COMPLEMENTARY TECHNOLOGIES
6.3.1 SPATIAL TRANSCRIPTOMICS AND SPATIAL OMICS
6.3.2 CRISPR/CAS GENOME EDITING
6.4 TECHNOLOGY/PRODUCT ROADMAP
6.5 PATENT ANALYSIS
6.5.1 TOP APPLICANTS/OWNERS (COMPANIES), FOR HUMAN ORGANOIDS PATENTS, 2015-2025
6.6 FUTURE APPLICATIONS
6.7 IMPACT OF AI/GEN AI ON THE GLOBAL HUMAN ORGANOIDS MARKET
6.7.1 TOP USE CASES AND MARKET POTENTIAL
6.7.2 CASE STUDIES OF AI IMPLEMENTATION IN THE GLOBAL HUMAN ORGANOIDS MARKET
6.7.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.7.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN THE GLOBAL HUMAN ORGANOIDS MARKET
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2 INDUSTRY STANDARDS
7.2 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
7.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8 CUSTOMER LANDSCAPE & BUYING BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 KEY BUYING CRITERIA FOR HUMAN ORGANOID MODELS, BY END USER
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS FROM END USERS
8.5 MARKET PROFITABILITY
9 HUMAN ORGANOIDS MARKET, BY OFFERING
9.1 INTRODUCTION
9.2 ORGANOID MODELS
9.2.1 READY-TO-USE ORGANOID MODELS
9.2.1.1 Increasing demand for ready-to-use organoid models to drive market growth
9.2.2 CUSTOMIZABLE ORGANOID MODELS
9.2.2.1 Rising demand for customizable organoid models to support market growth
9.3 SERVICES
9.3.1 MODEL DEVELOPMENT SERVICES
9.3.1.1 Rising demand for customized human organoid models to drive growth of model development services
9.3.2 ORGANOID MODEL-BASED TESTING SERVICES
10 HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE
10.1 INTRODUCTION
10.2 LIVER MODELS
10.2.1 RISING USE OF LIVER ORGANOID MODELS IN DRUG DISCOVERY AND TOXICITY TESTING TO DRIVE MARKET GROWTH
10.3 INTESTINAL & COLORECTAL MODELS
10.3.1 RISING USE OF INTESTINAL & COLORECTAL ORGANOID MODELS IN DISEASE MODELING AND DRUG SCREENING TO DRIVE MARKET GROWTH
10.4 KIDNEY MODELS
10.4.1 RISING USE OF KIDNEY ORGANOID MODELS IN DISEASE MODELING AND DRUG TOXICITY TESTING TO DRIVE MARKET GROWTH
10.5 PANCREATIC MODELS
10.5.1 RISING USE OF PANCREATIC ORGANOID MODELS IN DISEASE MODELING AND DRUG DISCOVERY TO DRIVE MARKET GROWTH
10.6 LUNG MODELS
10.6.1 RISING USE OF LUNG ORGANOID MODELS IN DISEASE MODELING AND DRUG SCREENING TO DRIVE MARKET GROWTH
10.7 HEART MODELS
10.7.1 RISING USE OF HEART ORGANOID MODELS IN CARDIOVASCULAR RESEARCH TO DRIVE MARKET GROWTH
10.8 OTHER ORGANOID MODELS
11 HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE
11.1 INTRODUCTION
11.2 ECM/MATRIGEL-BASED CULTURE
11.2.1 WIDESPREAD USE OF ECM/MATRIGEL-BASED CULTURE TO DRIVE HUMAN ORGANOIDS MARKET GROWTH
11.3 AIR-LIQUID INTERFACE CULTURE
11.3.1 INCREASING ADOPTION OF AIR-LIQUID INTERFACE CULTURE TO DRIVE MARKET GROWTH
11.4 SUSPENSION
11.4.1 RISING DEMAND FOR SCALABLE ORGANOID PRODUCTION TO DRIVE MARKET GROWTH
11.5 OTHER CULTURE TYPES
12 HUMAN ORGANOIDS MODELS MARKET, BY SOURCE
12.1 INTRODUCTION
12.2 PLURIPOTENT STEM CELLS
12.2.1 EXPANDING USE OF PLURIPOTENT STEM CELLS IN TISSUE-SPECIFIC ORGANOID DEVELOPMENT TO DRIVE MARKET GROWTH
12.3 ADULT STEM CELLS
12.3.1 RISING USE OF ADULT STEM CELLS FOR PHYSIOLOGICALLY RELEVANT ORGANOID MODELS TO DRIVE MARKET GROWTH
12.4 EMBRYONIC STEM CELLS
12.4.1 INCREASING USE OF EMBRYONIC STEM CELL-DERIVED ORGANOIDS IN DEVELOPMENTAL AND DISEASE RESEARCH TO SUPPORT MARKET GROWTH
12.5 OTHER SOURCES
13 HUMAN ORGANOIDS MARKET, BY DISEASE AREA
13.1 INTRODUCTION
13.2 ONCOLOGY
13.2.1 INCREASING ADOPTION OF TUMOR ORGANOIDS FOR DISEASE MODELING AND DRUG DEVELOPMENT TO DRIVE MARKET GROWTH
13.3 LIVER DISEASES/HEPATOLOGICAL DISORDERS
13.3.1 INCREASING ADOPTION OF LIVER ORGANOIDS FOR DISEASE MODELING AND DRUG DEVELOPMENT TO DRIVE MARKET GROWTH
13.4 GASTROINTESTINAL DISEASES
13.4.1 WIDE USAGE IN MODELING INFLAMMATORY BOWEL DISEASE AND MALIGNANCIES TO PROPEL MARKET
13.5 CARDIOVASCULAR DISEASES
13.5.1 RISING INCIDENCE OF CARDIOVASCULAR DISEASES TO DRIVE MARKET
13.6 INFECTIOUS DISEASES
13.6.1 USE OF ORGANOIDS IN DEVELOPING ANTIVIRAL DRUGS TO SUPPORT MARKET GROWTH
13.7 NEUROLOGICAL DISORDERS
13.7.1 GROWING INCIDENCE OF NEUROPSYCHIATRIC DISORDERS TO FUEL UPTAKE OF HUMAN ORGANOIDS
13.8 OTHER DISEASE AREAS
14 HUMAN ORGANOIDS MARKET, BY APPLICATION
14.1 INTRODUCTION
14.2 DRUG DISCOVERY & SCREENING
14.2.1 RISING USE OF HUMAN ORGANOIDS IN DRUG DISCOVERY AND SCREENING TO DRIVE MARKET GROWTH
14.3 DRUG TOXICITY & SAFETY TESTING
14.3.1 RISING USE OF HUMAN ORGANOIDS FOR DRUG TOXICITY AND SAFETY TESTING TO SUPPORT MARKET GROWTH
14.4 DISEASE MODELING
14.4.1 RISING APPLICATION OF HUMAN ORGANOIDS IN DISEASE MODELING TO DRIVE MARKET GROWTH
14.5 DEVELOPMENTAL BIOLOGY
14.5.1 INCREASING USE OF HUMAN ORGANOIDS IN DEVELOPMENTAL BIOLOGY TO SUPPORT MARKET GROWTH
14.6 PERSONALIZED MEDICINE
14.6.1 RISING ADOPTION OF PATIENT-DERIVED ORGANOIDS FOR PERSONALIZED MEDICINE TO DRIVE MARKET GROWTH
14.7 REGENERATIVE MEDICINE
14.7.1 EXPANDING APPLICATIONS OF HUMAN ORGANOIDS IN REGENERATIVE MEDICINE AND TISSUE ENGINEERING TO SUPPORT MARKET GROWTH
14.8 OTHER APPLICATIONS
15 HUMAN ORGANOID MODELS MARKET, BY END USER
15.1 INTRODUCTION
15.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
15.2.1 INCREASING ADOPTION OF HUMAN ORGANOID MODELS BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DRIVE MARKET GROWTH
15.3 ACADEMIC & RESEARCH INSTITUTES
15.3.1 RISING USE OF HUMAN ORGANOIDS IN ACADEMIC AND RESEARCH INSTITUTES TO DRIVE MARKET GROWTH
15.4 CROS/CRDMOS
15.4.1 INCREASING OUTSOURCING OF RESEARCH ACTIVITIES TO DRIVE ADOPTION OF HUMAN ORGANOID MODELS BY CROS/CRDMOS
15.5 OTHER END USERS
16 HUMAN ORGANOID SERVICES MARKET, BY END USER
16.1 INTRODUCTION
16.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
16.2.1 INCREASING OUTSOURCING OF ORGANOID DEVELOPMENT AND TESTING TO DRIVE MARKET GROWTH
16.3 ACADEMIC & RESEARCH INSTITUTES
16.3.1 RISING USE OF ORGANOID SERVICES IN ACADEMIC AND RESEARCH INSTITUTES TO DRIVE MARKET GROWTH
16.4 CROS/CRDMOS
16.4.1 INCREASING OUTSOURCING OF PRECLINICAL RESEARCH TO DRIVE ADOPTION OF ORGANOID SERVICES BY CROS/CRDMOS
16.5 OTHER END USERS
17 HUMAN ORGANOIDS MARKET, BY REGION
17.1 INTRODUCTION
17.2 NORTH AMERICA
17.2.1 US
17.2.1.1 Increasing adoption of human organoids in drug development to drive market growth
17.2.2 CANADA
17.2.2.1 Growing organoid research activities to support market growth in Canada
17.3 EUROPE
17.3.1 GERMANY
17.3.1.1 Strong pharmaceutical and research ecosystem to support market growth
17.3.2 UK
17.3.2.1 Increasing organoid research and drug discovery activities to drive market growth
17.3.3 FRANCE
17.3.3.1 Growing life sciences research and organoid applications to support market growth
17.3.4 ITALY
17.3.4.1 Expanding biomedical research to drive adoption of human organoids in Italy
17.3.5 SPAIN
17.3.5.1 Rising use of organoids in biomedical research to support market growth
17.3.6 REST OF EUROPE
17.3.6.1 Expanding organoid research across european countries to support market growth
17.4 ASIA PACIFIC
17.4.1 CHINA
17.4.1.1 Increasing pharmaceutical R&D and organoid research to drive market growth
17.4.2 JAPAN
17.4.2.1 Advancing regenerative medicine and drug research to support market growth
17.4.3 INDIA
17.4.3.1 Expanding pharmaceutical research and biotechnology activities to drive market growth
17.4.4 SOUTH KOREA
17.4.4.1 Growing biotechnology investments to support human organoid market growth
17.4.5 AUSTRALIA
17.4.5.1 Increasing biomedical research to support market growth in Australia
17.4.6 REST OF ASIA PACIFIC
17.4.6.1 Rising biotechnology research and drug development activities to support market growth
17.5 LATIN AMERICA
17.5.1 BRAZIL
17.5.1.1 Growing biomedical research to support human organoid market growth
17.5.2 MEXICO
17.5.2.1 Expanding pharmaceutical research to drive market growth in Mexico
17.5.3 REST OF LATIN AMERICA
17.5.3.1 Expanding pharmaceutical research to drive market growth in Mexico
17.6 MIDDLE EAST & AFRICA
17.6.1 GROWING INVESTMENTS IN LIFE SCIENCES RESEARCH TO SUPPORT MARKET GROWTH
18 COMPETITIVE LANDSCAPE
18.1 INTRODUCTION
18.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
18.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HUMAN ORGANOIDS MARKET
18.3 REVENUE ANALYSIS, 2023-2025
18.4 MARKET SHARE ANALYSIS, 2025
18.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
18.5.1 STARS
18.5.2 EMERGING LEADERS
18.5.3 PERVASIVE PLAYERS
18.5.4 PARTICIPANTS
18.5.5 COMPANY FOOTPRINT, KEY PLAYERS, 2025
18.5.5.1 Company footprint
18.5.5.2 Region footprint
18.5.5.3 Offering footprint
18.5.5.4 Source footprint
18.5.5.5 Application footprint
18.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
18.6.1 PROGRESSIVE COMPANIES
18.6.2 RESPONSIVE COMPANIES
18.6.3 DYNAMIC COMPANIES
18.6.4 STARTING BLOCKS
18.6.5 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS, 2025
18.6.5.1 Detailed list of key startups/SMEs
18.6.5.2 Competitive benchmarking of key startups/SMEs
18.7 COMPANY VALUATION AND FINANCIAL METRICS
18.8 BRAND COMPARATIVE ANALYSIS
18.9 COMPETITIVE SCENARIO
18.9.1 PRODUCT/ SERVICE LAUNCHES
18.9.2 DEALS
18.9.3 OTHER DEVELOPMENTS
19 COMPANY PROFILES
19.1 KEY PLAYERS
19.1.1 MERCK KGAA
19.1.1.1 Business overview
19.1.1.2 Products/Services offered
19.1.1.3 Recent developments
19.1.1.3.1 Deals
19.1.1.3.2 Expansions
19.1.1.4 Analyst's view
19.1.1.4.1 Right to win
19.1.1.4.2 Strategic choices
19.1.1.4.3 Weaknesses and competitive threats
19.1.2 DANAHER CORPORATION
19.1.2.1 Business overview
19.1.2.2 Products/Services offered
19.1.2.3 Recent developments
19.1.2.3.1 Other developments
19.1.2.4 Analyst's view
19.1.2.4.1 Right to win
19.1.2.4.2 Strategic choices
19.1.2.4.3 Weaknesses and competitive threats
19.1.3 SAMSUNG BIOLOGICS
19.1.3.1 Business overview
19.1.3.2 Products/Services offered
19.1.3.3 Recent developments
19.1.3.3.1 Service launches
19.1.3.4 Analyst's view
19.1.3.4.1 Right to win
19.1.3.4.2 Strategic choices
19.1.3.4.3 Weaknesses and competitive threats
19.1.4 WUXI APPTEC
19.1.4.1 Business overview
19.1.4.2 Products/Services offered
19.1.4.3 Recent developments
19.1.4.3.1 Other developments
19.1.4.4 Analyst's view
19.1.4.4.1 Right to win
19.1.4.4.2 Strategic choices
19.1.4.4.3 Weaknesses and competitive threats
19.1.5 EVOTEC SE
19.1.5.1 Business overview
19.1.5.2 Products/Services offered
19.1.5.3 Recent developments
19.1.5.3.1 Deals
19.1.5.4 Analyst's view
19.1.5.4.1 Right to win
19.1.5.4.2 Strategic choices
19.1.5.4.3 Weaknesses and competitive threats
19.1.6 CHAMPIONS ONCOLOGY
19.1.6.1 Business overview
19.1.6.2 Products/Services offered
19.1.6.3 Recent developments
19.1.6.3.1 Other developments
19.1.7 ACROBIOSYSTEMS
19.1.7.1 Business overview
19.1.7.2 Products/Services offered
19.1.8 BIOMORGAN LIMITED
19.1.8.1 Business overview
19.1.8.2 Products/Services offered
19.1.8.3 Recent developments
19.1.8.3.1 Deals
19.1.9 ORGANOID SCIENCES, INC.
19.1.9.1 Business overview
19.1.9.2 Products/Services offered
19.1.9.3 Recent developments
19.1.9.3.1 Expansions
19.1.9.3.2 Other developments
19.1.10 JSR CORPORATION
19.1.10.1 Business overview
19.1.10.2 Products/Services offered
19.1.10.3 Recent developments
19.1.10.3.1 Deals
19.1.11 THERMO FISHER SCIENTIFIC INC.
19.1.11.1 Business overview
19.1.11.2 Products/Services offered
19.1.11.3 Recent developments
19.1.11.3.1 Product launches
19.1.11.3.2 Deals
19.1.12 BRUKER CORPORATION
19.1.12.1 Business overview
19.1.12.2 Products/Services offered
19.1.12.3 Recent developments
19.1.12.3.1 Product & service launches
19.1.12.3.2 Deals
19.1.13 CHARLES RIVER LABORATORIES
19.1.13.1 Business overview
19.1.13.2 Products/Services offered
19.1.14 PHARMARON
19.1.14.1 Business overview
19.1.14.2 Products/Services offered
19.1.15 VIVOSIM LABS, INC.
19.1.15.1 Business overview
19.1.15.2 Products/Services offered
19.1.15.3 Recent developments
19.1.15.3.1 Product launches
19.1.15.3.2 Deals
19.1.16 STEMCELL TECHNOLOGIES
19.1.16.1 Business overview
19.1.16.2 Products/Services offered
19.1.16.2.1 Expansions
19.2 OTHER PLAYERS
19.2.1 SCREENIN3D
19.2.2 DISCOVERY LIFE SCIENCES
19.2.3 LIDE BIOTECH
19.2.4 INNOSER
19.2.5 CENSO BIOTECHNOLOGIES LTD
19.2.6 CREATIVE BIOLABS
19.2.7 PANDORUM TECHNOLOGIES PVT. LTD.
19.2.8 INVITROCUE
19.2.9 NEYROBLASTGX LLC
19.2.10 DEXORGEN
19.2.11 PIXLBIO
20 RESEARCH METHODOLOGY
20.1 RESEARCH DATA
20.2 RESEARCH APPROACH
20.2.1 SECONDARY DATA
20.2.1.1 Key secondary sources
20.2.1.2 Key data from secondary research
20.2.2 PRIMARY DATA
20.2.2.1 Key data from primary sources
20.2.2.2 Breakdown of primary interviews
20.3 MARKET SIZE ESTIMATION
20.3.1 GLOBAL HUMAN ORGANOIDS MARKET ESTIMATION, 2025
20.3.1.1 Approach 1: company revenue analysis-based estimation (bottom-up)
20.3.1.2 Approach 2: secondary research
20.3.1.3 Approach 3: primary research
20.3.1.4 Key industry insights
20.3.1.5 Approach 3: MnM repository analysis
20.3.2 SEGMENTAL MARKET SIZE ESTIMATION, 2025
20.4 MARKET GROWTH RATE PROJECTIONS
20.4.1 CAGR PROJECTIONS
20.5 DATA TRIANGULATION
20.6 RESEARCH ASSUMPTIONS
20.7 RESEARCH LIMITATIONS
20.8 RISK ASSESSMENT
21 APPENDIX
21.1 DISCUSSION GUIDE
21.2 KNOWLEDGESTORE: THE SUBSCRIPTION PORTAL
21.3 CUSTOMIZATION OPTIONS
21.4 RELATED REPORTS
21.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 HUMAN ORGANOIDS MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2 HUMAN ORGANOIDS MARKET: IMPACT ANALYSIS
TABLE 3 GLOBAL HUMAN ORGANOIDS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 4 GLOBAL HUMAN ORGANOIDS MARKET: KEY MODEL AND SERVICE PROVIDERS
TABLE 5 GLOBAL HUMAN ORGANOIDS MARKET: PRODUCTION SITES AND CAPABILITY DEVELOPMENTS
TABLE 6 AVERAGE SELLING PRICE OF HUMAN ORGANOIDS, BY PRODUCT/ SERVICE, 2025
TABLE 7 GLOBAL HUMAN ORGANOIDS MARKET: KEY CONFERENCES & EVENTS,2026-2027
TABLE 8 HUMAN ORGANOIDS MARKET: INDICATIVE LIST OF PATENTS, 2024-2025
TABLE 9 CASE STUDIES OF AI IMPLEMENTATION IN THE GLOBAL HUMAN ORGANOIDS MARKET
TABLE 10 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN THE GLOBAL HUMAN ORGANOIDS MARKET
TABLE 11 HUMAN ORGANOIDS REGULATORY GUIDANCE/FRAMEWORK, BY OFFERING
TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 ILLUSTRATIVE STAKEHOLDER INFLUENCE, BY MODEL TYPE (%)
TABLE 17 ILLUSTRATIVE BUYING CRITERIA, BY END USER
TABLE 18 HUMAN ORGANOIDS MARKET, BY OFFERING, 2023-2031 (USD MILLION)
TABLE 19 HUMAN ORGANOIDS MODELS MARKET, BY TYPE, 2023-2031 (USD MILLION)
TABLE 20 HUMAN ORGANOID MODELS MARKET, BY REGION, 2023-2031 (USD MILLION)
TABLE 21 NORTH AMERICA: HUMAN ORGANOID MODELS MARKET, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 22 EUROPE: HUMAN ORGANOID MODELS MARKET, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 23 ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 24 LATIN AMERICA: HUMAN ORGANOID MODELS MARKET, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 25 READY-TO-USE HUMAN ORGANOID MODELS MARKET, BY REGION,2023-2031 (USD MILLION)
TABLE 26 NORTH AMERICA: READY-TO-USE HUMAN ORGANOID MODELS MARKET,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 27 EUROPE: READY-TO-USE HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 28 ASIA PACIFIC: READY-TO-USE HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 29 LATIN AMERICA: READY-TO-USE HUMAN ORGANOID MODELS MARKET,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 30 CUSTOMIZABLE HUMAN ORGANOID MODELS MARKET, BY REGION,2023-2031 (USD MILLION)
TABLE 31 NORTH AMERICA: CUSTOMIZABLE HUMAN ORGANOID MODELS MARKET,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 32 EUROPE: CUSTOMIZABLE HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 33 ASIA PACIFIC: CUSTOMIZABLE HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 34 LATIN AMERICA: CUSTOMIZABLE HUMAN ORGANOID MODELS MARKET,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 35 HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE,2023-2031 (USD MILLION)
TABLE 36 HUMAN ORGANOID MODEL SERVICES MARKET, BY REGION,2023-2031 (USD MILLION)
TABLE 37 NORTH AMERICA: HUMAN ORGANOID MODEL SERVICES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 38 EUROPE: HUMAN ORGANOID MODEL SERVICES MARKET, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 39 ASIA PACIFIC: HUMAN ORGANOID MODEL SERVICES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 40 LATIN AMERICA: HUMAN ORGANOID MODEL SERVICES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 41 HUMAN ORGANOID MODEL DEVELOPMENT SERVICES MARKET, BY REGION, 2023-2031 (USD MILLION)
TABLE 42 NORTH AMERICA: HUMAN ORGANOID MODEL DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 43 EUROPE: HUMAN ORGANOID MODEL DEVELOPMENT SERVICES MARKET,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 44 ASIA PACIFIC: HUMAN ORGANOID MODEL DEVELOPMENT SERVICES MARKET,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 45 LATIN AMERICA: HUMAN ORGANOID MODEL DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 46 HUMAN ORGANOID MODEL-BASED TESTING SERVICES MARKET, BY REGION, 2023-2031 (USD MILLION)
TABLE 47 NORTH AMERICA: HUMAN ORGANOID MODEL-BASED TESTING SERVICES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 48 EUROPE: HUMAN ORGANOID MODEL-BASED TESTING SERVICES MARKET,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 49 ASIA PACIFIC: HUMAN ORGANOID MODEL-BASED TESTING SERVICES MARKET,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 50 LATIN AMERICA: HUMAN ORGANOID MODEL-BASED TESTING SERVICES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 51 HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE,2023-2031 (USD MILLION)
TABLE 52 LIVER MODELS MARKET, BY REGION, 2023-2031 (USD MILLION)
TABLE 53 NORTH AMERICA: LIVER MODELS MARKET, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 54 EUROPE: LIVER MODELS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 55 ASIA PACIFIC: LIVER MODELS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 56 LATIN AMERICA: LIVER MODELS MARKET, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 57 INTESTINAL & COLORECTAL MODELS MARKET, BY REGION,2023-2031 (USD MILLION)
TABLE 58 NORTH AMERICA: INTESTINAL & COLORECTAL MODELS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 59 EUROPE: INTESTINAL & COLORECTAL MODELS MARKET, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 60 ASIA PACIFIC: INTESTINAL & COLORECTAL MODELS MARKET, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 61 LATIN AMERICA: INTESTINAL & COLORECTAL MODELS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 62 KIDNEY MODELS MARKET, BY REGION, 2023-2031 (USD MILLION)
TABLE 63 NORTH AMERICA: KIDNEY MODELS MARKET, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 64 EUROPE: KIDNEY MODELS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 65 ASIA PACIFIC: KIDNEY MODELS MARKET, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 66 LATIN AMERICA: KIDNEY MODELS MARKET, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 67 PANCREATIC MODELS MARKET, BY REGION, 2023-2031 (USD MILLION)
TABLE 68 NORTH AMERICA: PANCREATIC MODELS MARKET, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 69 EUROPE: PANCREATIC MODELS MARKET, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 70 ASIA PACIFIC: PANCREATIC MODELS MARKET, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 71 LATIN AMERICA: PANCREATIC MODELS MARKET, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 72 LUNG MODELS MARKET, BY REGION, 2023-2031 (USD MILLION)
TABLE 73 NORTH AMERICA: LUNG MODELS MARKET, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 74 EUROPE: LUNG MODELS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 75 ASIA PACIFIC: LUNG MODELS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 76 LATIN AMERICA: LUNG MODELS MARKET, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 77 HEART MODELS MARKET, BY REGION, 2023-2031 (USD MILLION)
TABLE 78 NORTH AMERICA: HEART MODELS MARKET, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 79 EUROPE: HEART MODELS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 80 ASIA PACIFIC: HEART MODELS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 81 LATIN AMERICA: HEART MODELS MARKET, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 82 OTHER HUMAN ORGANOID MODELS MARKET, BY REGION,2023-2031 (USD MILLION)
TABLE 83 NORTH AMERICA: OTHER HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 84 EUROPE: OTHER HUMAN ORGANOID MODELS MARKET, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 85 ASIA PACIFIC: OTHER HUMAN ORGANOID MODELS MARKET, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 86 LATIN AMERICA: OTHER HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 87 HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE,2023-2031 (USD MILLION)
TABLE 88 HUMAN ORGANOID MODELS MARKET FOR ECM/MATRIGEL-BASED CULTURE,BY REGION, 2023-2031 (USD MILLION)
TABLE 89 NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR ECM/MATRIGEL-BASED CULTURE, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 90 EUROPE: HUMAN ORGANOID MODELS MARKET FOR ECM/MATRIGEL-BASED CULTURE, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 91 ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR ECM/MATRIGEL-BASED CULTURE, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 92 LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR ECM/MATRIGEL-BASED CULTURE, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 93 HUMAN ORGANOID MODELS MARKET FOR AIR-LIQUID INTERFACE, BY REGION, 2023-2031 (USD MILLION)
TABLE 94 NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR AIR-LIQUID INTERFACE, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 95 EUROPE: HUMAN ORGANOID MODELS MARKET FOR AIR-LIQUID INTERFACE,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 96 ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR AIR-LIQUID INTERFACE, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 97 LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR AIR-LIQUID INTERFACE, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 98 HUMAN ORGANOID MODELS MARKET FOR SUSPENSION, BY REGION,2023-2031 (USD MILLION)
TABLE 99 NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR SUSPENSION,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 100 EUROPE: HUMAN ORGANOID MODELS MARKET FOR SUSPENSION, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 101 ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR SUSPENSION,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 102 LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR SUSPENSION,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 103 HUMAN ORGANOID MODELS MARKET FOR OTHER CULTURE TYPES, BY REGION, 2023-2031 (USD MILLION)
TABLE 104 NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR OTHER CULTURE TYPES, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 105 EUROPE: HUMAN ORGANOID MODELS MARKET FOR OTHER CULTURE TYPES,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 106 ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR OTHER CULTURE TYPES, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 107 LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR OTHER CULTURE TYPES, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 108 HUMAN ORGANOIDS MODELS MARKET, BY SOURCE, 2023-2031 (USD MILLION)
TABLE 109 PLURIPOTENT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET,BY REGION, 2023-2031 (USD MILLION)
TABLE 110 NORTH AMERICA: PLURIPOTENT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 111 EUROPE: PLURIPOTENT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 112 ASIA PACIFIC: PLURIPOTENT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 113 LATIN AMERICA: PLURIPOTENT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 114 ADULT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY REGION, 2023-2031 (USD MILLION)
TABLE 115 NORTH AMERICA: ADULT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 116 EUROPE: ADULT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 117 ASIA PACIFIC: ADULT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 118 LATIN AMERICA: ADULT STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 119 EMBRYONIC STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET,BY REGION, 2023-2031 (USD MILLION)
TABLE 120 NORTH AMERICA: EMBRYONIC STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 121 EUROPE: EMBRYONIC STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 122 ASIA PACIFIC: EMBRYONIC STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 123 LATIN AMERICA: EMBRYONIC STEM CELLS-BASED HUMAN ORGANOID MODELS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 124 OTHER HUMAN ORGANOID MODEL SOURCES MARKET, BY REGION,2023-2031 (USD MILLION)
TABLE 125 NORTH AMERICA: OTHER HUMAN ORGANOID MODEL SOURCES MARKET,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 126 EUROPE: OTHER HUMAN ORGANOID MODEL SOURCES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 127 ASIA PACIFIC: OTHER HUMAN ORGANOID MODEL SOURCES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 128 LATIN AMERICA: OTHER HUMAN ORGANOID MODEL SOURCES MARKET,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 129 HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2023-2031 (USD MILLION)
TABLE 130 INCIDENCE OF CANCER CASES WORLDWIDE, IN 2022 VS 2045, BY CANCER TYPE
TABLE 131 HUMAN ORGANOID MARKET FOR ONCOLOGY, BY REGION,2023-2031 (USD MILLION)
TABLE 132 NORTH AMERICA: HUMAN ORGANOID MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 133 EUROPE: HUMAN ORGANOID MARKET FOR ONCOLOGY, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 134 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR ONCOLOGY, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 135 LATIN AMERICA: HUMAN ORGANOID MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 136 HUMAN ORGANOID MARKET FOR LIVER DISEASES/HEPATOLOGICAL DISORDERS, BY REGION, 2023-2031 (USD MILLION)
TABLE 137 NORTH AMERICA: HUMAN ORGANOID MARKET FOR LIVER DISEASES/HEPATOLOGICAL DISORDERS, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 138 EUROPE: HUMAN ORGANOID MARKET FOR LIVER DISEASES/HEPATOLOGICAL DISORDERS, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 139 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR LIVER DISEASES/HEPATOLOGICAL DISORDERS, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 140 LATIN AMERICA: HUMAN ORGANOID MARKET FOR LIVER DISEASES/HEPATOLOGICAL DISORDERS, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 141 HUMAN ORGANOID MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023-2031 (USD MILLION)
TABLE 142 NORTH AMERICA: HUMAN ORGANOID MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 143 EUROPE: HUMAN ORGANOID MARKET FOR GASTROINTESTINAL DISEASES,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 144 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR GASTROINTESTINAL DISEASES,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 145 LATIN AMERICA: HUMAN ORGANOID MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 146 HUMAN ORGANOID MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023-2031 (USD MILLION)
TABLE 147 NORTH AMERICA: HUMAN ORGANOID MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 148 EUROPE: HUMAN ORGANOID MARKET FOR CARDIOVASCULAR DISEASES,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 149 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR CARDIOVASCULAR DISEASES,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 150 LATIN AMERICA: HUMAN ORGANOID MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 151 HUMAN ORGANOID MARKET FOR INFECTIOUS DISEASES, BY REGION,2023-2031 (USD MILLION)
TABLE 152 NORTH AMERICA: HUMAN ORGANOID MARKET FOR INFECTIOUS DISEASES,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 153 EUROPE: HUMAN ORGANOID MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 154 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR INFECTIOUS DISEASES,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 155 LATIN AMERICA: HUMAN ORGANOID MARKET FOR INFECTIOUS DISEASES,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 156 HUMAN ORGANOID MARKET FOR NEUROLOGICAL DISORDERS, BY REGION,2023-2031 (USD MILLION)
TABLE 157 NORTH AMERICA: HUMAN ORGANOID MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 158 EUROPE: HUMAN ORGANOID MARKET FOR NEUROLOGICAL DISORDERS,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 159 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR NEUROLOGICAL DISORDERS,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 160 LATIN AMERICA: HUMAN ORGANOID MARKET FOR NEUROLOGICAL DISORDERS,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 161 HUMAN ORGANOID MARKET FOR OTHER DISEASE AREAS, BY REGION,2023-2031 (USD MILLION)
TABLE 162 NORTH AMERICA: HUMAN ORGANOID MARKET FOR OTHER DISEASE AREAS,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 163 EUROPE: HUMAN ORGANOID MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 164 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR OTHER DISEASE AREAS,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 165 LATIN AMERICA: HUMAN ORGANOID MARKET FOR OTHER DISEASE AREAS,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 166 HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
TABLE 167 HUMAN ORGANOID MARKET FOR DRUG DISCOVERY & SCREENING, BY REGION, 2023-2031 (USD MILLION)
TABLE 168 NORTH AMERICA: HUMAN ORGANOID MARKET FOR DRUG DISCOVERY & SCREENING, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 169 EUROPE: HUMAN ORGANOID MARKET FOR DRUG DISCOVERY & SCREENING,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 170 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR DRUG DISCOVERY & SCREENING, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 171 LATIN AMERICA: HUMAN ORGANOID MARKET FOR DRUG DISCOVERY & SCREENING, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 172 HUMAN ORGANOID MARKET FOR DRUG TOXICITY & SAFETY TESTING, BY REGION, 2023-2031 (USD MILLION)
TABLE 173 NORTH AMERICA: HUMAN ORGANOID MARKET FOR DRUG TOXICITY & SAFETY TESTING, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 174 EUROPE: HUMAN ORGANOID MARKET FOR DRUG TOXICITY & SAFETY TESTING,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 175 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR DRUG TOXICITY & SAFETY TESTING, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 176 LATIN AMERICA: HUMAN ORGANOID MARKET FOR DRUG TOXICITY & SAFETY TESTING, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 177 HUMAN ORGANOID MARKET FOR DISEASE MODELING, BY REGION,2023-2031 (USD MILLION)
TABLE 178 NORTH AMERICA: HUMAN ORGANOID MARKET FOR DISEASE MODELING,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 179 EUROPE: HUMAN ORGANOID MARKET FOR DISEASE MODELING, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 180 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR DISEASE MODELING, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 181 LATIN AMERICA: HUMAN ORGANOID MARKET FOR DISEASE MODELING,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 182 HUMAN ORGANOID MARKET FOR DEVELOPMENTAL BIOLOGY, BY REGION,2023-2031 (USD MILLION)
TABLE 183 NORTH AMERICA: HUMAN ORGANOID MARKET FOR DEVELOPMENTAL BIOLOGY,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 184 EUROPE: HUMAN ORGANOID MARKET FOR DEVELOPMENTAL BIOLOGY,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 185 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR DEVELOPMENTAL BIOLOGY,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 186 LATIN AMERICA: HUMAN ORGANOID MARKET FOR DEVELOPMENTAL BIOLOGY,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 187 HUMAN ORGANOID MARKET FOR PERSONALIZED MEDICINE, BY REGION,2023-2031 (USD MILLION)
TABLE 188 NORTH AMERICA: HUMAN ORGANOID MARKET FOR PERSONALIZED MEDICINE,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 189 EUROPE: HUMAN ORGANOID MARKET FOR PERSONALIZED MEDICINE,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 190 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR PERSONALIZED MEDICINE,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 191 LATIN AMERICA: HUMAN ORGANOID MARKET FOR PERSONALIZED MEDICINE,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 192 HUMAN ORGANOID MARKET FOR REGENERATIVE MEDICINE, BY REGION,2023-2031 (USD MILLION)
TABLE 193 NORTH AMERICA: HUMAN ORGANOID MARKET FOR REGENERATIVE MEDICINE,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 194 EUROPE: HUMAN ORGANOID MARKET FOR REGENERATIVE MEDICINE,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 195 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR REGENERATIVE MEDICINE,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 196 LATIN AMERICA: HUMAN ORGANOID MARKET FOR REGENERATIVE MEDICINE,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 197 HUMAN ORGANOID MARKET FOR OTHER APPLICATIONS, BY REGION,2023-2031 (USD MILLION)
TABLE 198 NORTH AMERICA: HUMAN ORGANOID MARKET FOR OTHER APPLICATIONS,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 199 EUROPE: HUMAN ORGANOID MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 200 ASIA PACIFIC: HUMAN ORGANOID MARKET FOR OTHER APPLICATIONS,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 201 LATIN AMERICA: HUMAN ORGANOID MARKET FOR OTHER APPLICATIONS,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 202 HUMAN ORGANOIDS MODELS MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 203 HUMAN ORGANOID MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2031 (USD MILLION)
TABLE 204 NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 205 EUROPE: HUMAN ORGANOID MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 206 ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 207 LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 208 HUMAN ORGANOID MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2031 (USD MILLION)
TABLE 209 NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 210 EUROPE: HUMAN ORGANOID MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 211 ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 212 LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 213 HUMAN ORGANOID MODELS MARKET FOR CROS/CRDMOS, BY REGION,2023-2031 (USD MILLION)
TABLE 214 NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR CROS/CRDMOS,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 215 EUROPE: HUMAN ORGANOID MODELS MARKET FOR CROS/CRDMOS,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 216 ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR CROS/CRDMOS,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 217 LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR CROS/CRDMOS,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 218 HUMAN ORGANOID MODELS MARKET FOR OTHER END USERS, BY REGION,2023-2031 (USD MILLION)
TABLE 219 NORTH AMERICA: HUMAN ORGANOID MODELS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 220 EUROPE: HUMAN ORGANOID MODELS MARKET FOR OTHER END USERS,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 221 ASIA PACIFIC: HUMAN ORGANOID MODELS MARKET FOR OTHER END USERS,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 222 LATIN AMERICA: HUMAN ORGANOID MODELS MARKET FOR OTHER END USERS,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 223 HUMAN ORGANOID SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
TABLE 224 HUMAN ORGANOID SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2031 (USD MILLION)
TABLE 225 NORTH AMERICA: HUMAN ORGANOID SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 226 EUROPE: HUMAN ORGANOID SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 227 ASIA PACIFIC: HUMAN ORGANOID SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 228 LATIN AMERICA: HUMAN ORGANOID SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 229 HUMAN ORGANOID SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2031 (USD MILLION)
TABLE 230 NORTH AMERICA: HUMAN ORGANOID SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 231 EUROPE: HUMAN ORGANOID SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 232 ASIA PACIFIC: HUMAN ORGANOID SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 233 LATIN AMERICA: HUMAN ORGANOID SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 234 HUMAN ORGANOID SERVICES MARKET FOR CROS/CRDMOS, BY REGION,2023-2031 (USD MILLION)
TABLE 235 NORTH AMERICA: HUMAN ORGANOID SERVICES MARKET FOR CROS/CRDMOS,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 236 EUROPE: HUMAN ORGANOID SERVICES MARKET FOR CROS/CRDMOS,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 237 ASIA PACIFIC: HUMAN ORGANOID SERVICES MARKET FOR CROS/CRDMOS,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 238 LATIN AMERICA: HUMAN ORGANOID SERVICES MARKET FOR CROS/CRDMOS,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 239 HUMAN ORGANOID SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023-2031 (USD MILLION)
TABLE 240 NORTH AMERICA: HUMAN ORGANOID SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 241 EUROPE: HUMAN ORGANOID SERVICES MARKET FOR OTHER END USERS,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 242 ASIA PACIFIC: HUMAN ORGANOID SERVICES MARKET FOR OTHER END USERS,BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 243 LATIN AMERICA: HUMAN ORGANOID SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 244 HUMAN ORGANOIDS MARKET, BY REGION, 2023-2031 (USD MILLION)
TABLE 245 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 246 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY OFFERING,2023-2031 (USD MILLION)
TABLE 247 NORTH AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY TYPE,2023-2031 (USD MILLION)
TABLE 248 NORTH AMERICA: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE, 2023-2031 (USD MILLION)
TABLE 249 NORTH AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE,2023-2031 (USD MILLION)
TABLE 250 NORTH AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE, 2023-2031 (USD MILLION)
TABLE 251 NORTH AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE,2023-2031 (USD MILLION)
TABLE 252 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,2023-2031 (USD MILLION)
TABLE 253 NORTH AMERICA: HUMAN ORGANOIDS MARKET, BY APPLICATION,2023-2031 (USD MILLION)
TABLE 254 NORTH AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 255 NORTH AMERICA: HUMAN ORGANOID SERVICES MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 256 US: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023-2031 (USD MILLION)
TABLE 257 US: HUMAN ORGANOIDS MODELS MARKET, BY TYPE, 2023-2031 (USD MILLION)
TABLE 258 US: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE,2023-2031 (USD MILLION)
TABLE 259 US: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE,2023-2031 (USD MILLION)
TABLE 260 US: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE,2023-2031 (USD MILLION)
TABLE 261 US: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE,2023-2031 (USD MILLION)
TABLE 262 US: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2023-2031 (USD MILLION)
TABLE 263 US: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
TABLE 264 US: HUMAN ORGANOIDS MODELS MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 265 US: HUMAN ORGANOID SERVICES MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 266 CANADA: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023-2031 (USD MILLION)
TABLE 267 CANADA: HUMAN ORGANOIDS MODELS MARKET, BY TYPE,2023-2031 (USD MILLION)
TABLE 268 CANADA: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE,2023-2031 (USD MILLION)
TABLE 269 CANADA: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE,2023-2031 (USD MILLION)
TABLE 270 CANADA: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE,2023-2031 (USD MILLION)
TABLE 271 CANADA: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE,2023-2031 (USD MILLION)
TABLE 272 CANADA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,2023-2031 (USD MILLION)
TABLE 273 CANADA: HUMAN ORGANOIDS MARKET, BY APPLICATION,2023-2031 (USD MILLION)
TABLE 274 CANADA: HUMAN ORGANOIDS MODELS MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 275 CANADA: HUMAN ORGANOID SERVICES MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 276 EUROPE: HUMAN ORGANOIDS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
TABLE 277 EUROPE: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023-2031 (USD MILLION)
TABLE 278 EUROPE: HUMAN ORGANOIDS MODELS MARKET, BY TYPE,2023-2031 (USD MILLION)
TABLE 279 EUROPE: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE,2023-2031 (USD MILLION)
TABLE 280 EUROPE: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE,2023-2031 (USD MILLION)
TABLE 281 EUROPE: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE,2023-2031 (USD MILLION)
TABLE 282 EUROPE: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE,2023-2031 (USD MILLION)
TABLE 283 EUROPE: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,2023-2031 (USD MILLION)
TABLE 284 EUROPE: HUMAN ORGANOIDS MARKET, BY APPLICATION,2023-2031 (USD MILLION)
TABLE 285 EUROPE: HUMAN ORGANOIDS MODELS MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 286 EUROPE: HUMAN ORGANOID SERVICES MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 287 GERMANY: HUMAN ORGANOIDS MARKET, BY OFFERING,2023-2031 (USD MILLION)
TABLE 288 GERMANY: HUMAN ORGANOIDS MODELS MARKET, BY TYPE,2023-2031 (USD MILLION)
TABLE 289 GERMANY: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE,2023-2031 (USD MILLION)
TABLE 290 GERMANY: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE,2023-2031 (USD MILLION)
TABLE 291 GERMANY: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE,2023-2031 (USD MILLION)
TABLE 292 GERMANY: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE,2023-2031 (USD MILLION)
TABLE 293 GERMANY: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,2023-2031 (USD MILLION)
TABLE 294 GERMANY: HUMAN ORGANOIDS MARKET, BY APPLICATION,2023-2031 (USD MILLION)
TABLE 295 GERMANY: HUMAN ORGANOIDS MODELS MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 296 GERMANY: HUMAN ORGANOID SERVICES MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 297 UK: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023-2031 (USD MILLION)
TABLE 298 UK: HUMAN ORGANOIDS MODELS MARKET, BY TYPE, 2023-2031 (USD MILLION)
TABLE 299 UK: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE,2023-2031 (USD MILLION)
TABLE 300 UK: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE,2023-2031 (USD MILLION)
TABLE 301 UK: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE,2023-2031 (USD MILLION)
TABLE 302 UK: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE,2023-2031 (USD MILLION)
TABLE 303 UK: HUMAN ORGANOIDS MARKET, BY DISEASE AREA, 2023-2031 (USD MILLION)
TABLE 304 UK: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
TABLE 305 UK: HUMAN ORGANOIDS MODELS MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 306 UK: HUMAN ORGANOID SERVICES MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 307 FRANCE: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023-2031 (USD MILLION)
TABLE 308 FRANCE: HUMAN ORGANOIDS MODELS MARKET, BY TYPE,2023-2031 (USD MILLION)
TABLE 309 FRANCE: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE,2023-2031 (USD MILLION)
TABLE 310 FRANCE: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE,2023-2031 (USD MILLION)
TABLE 311 FRANCE: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE,2023-2031 (USD MILLION)
TABLE 312 FRANCE: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE,2023-2031 (USD MILLION)
TABLE 313 FRANCE: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,2023-2031 (USD MILLION)
TABLE 314 FRANCE: HUMAN ORGANOIDS MARKET, BY APPLICATION,2023-2031 (USD MILLION)
TABLE 315 FRANCE: HUMAN ORGANOIDS MODELS MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 316 FRANCE: HUMAN ORGANOID SERVICES MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 317 ITALY: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023-2031 (USD MILLION)
TABLE 318 ITALY: HUMAN ORGANOIDS MODELS MARKET, BY TYPE,2023-2031 (USD MILLION)
TABLE 319 ITALY: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE,2023-2031 (USD MILLION)
TABLE 320 ITALY: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE,2023-2031 (USD MILLION)
TABLE 321 ITALY: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE,2023-2031 (USD MILLION)
TABLE 322 ITALY: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE,2023-2031 (USD MILLION)
TABLE 323 ITALY: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,2023-2031 (USD MILLION)
TABLE 324 ITALY: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
TABLE 325 ITALY: HUMAN ORGANOIDS MODELS MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 326 ITALY: HUMAN ORGANOID SERVICES MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 327 SPAIN: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023-2031 (USD MILLION)
TABLE 328 SPAIN: HUMAN ORGANOIDS MODELS MARKET, BY TYPE,2023-2031 (USD MILLION)
TABLE 329 SPAIN: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE,2023-2031 (USD MILLION)
TABLE 330 SPAIN: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE,2023-2031 (USD MILLION)
TABLE 331 SPAIN: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE,2023-2031 (USD MILLION)
TABLE 332 SPAIN: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE,2023-2031 (USD MILLION)
TABLE 333 SPAIN: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,2023-2031 (USD MILLION)
TABLE 334 SPAIN: HUMAN ORGANOIDS MARKET, BY APPLICATION,2023-2031 (USD MILLION)
TABLE 335 SPAIN: HUMAN ORGANOIDS MODELS MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 336 SPAIN: HUMAN ORGANOID SERVICES MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 337 REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY OFFERING,2023-2031 (USD MILLION)
TABLE 338 REST OF EUROPE: HUMAN ORGANOIDS MODELS MARKET, BY TYPE,2023-2031 (USD MILLION)
TABLE 339 REST OF EUROPE: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE, 2023-2031 (USD MILLION)
TABLE 340 REST OF EUROPE: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE, 2023-2031 (USD MILLION)
TABLE 341 REST OF EUROPE: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE, 2023-2031 (USD MILLION)
TABLE 342 REST OF EUROPE: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE,2023-2031 (USD MILLION)
TABLE 343 REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,2023-2031 (USD MILLION)
TABLE 344 REST OF EUROPE: HUMAN ORGANOIDS MARKET, BY APPLICATION,2023-2031 (USD MILLION)
TABLE 345 REST OF EUROPE: HUMAN ORGANOIDS MODELS MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 346 REST OF EUROPE: HUMAN ORGANOID SERVICES MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 347 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 348 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY OFFERING,2023-2031 (USD MILLION)
TABLE 349 ASIA PACIFIC: HUMAN ORGANOIDS MODELS MARKET, BY TYPE,2023-2031 (USD MILLION)
TABLE 350 ASIA PACIFIC: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE,2023-2031 (USD MILLION)
TABLE 351 ASIA PACIFIC: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE,2023-2031 (USD MILLION)
TABLE 352 ASIA PACIFIC: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE,2023-2031 (USD MILLION)
TABLE 353 ASIA PACIFIC: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE,2023-2031 (USD MILLION)
TABLE 354 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,2023-2031 (USD MILLION)
TABLE 355 ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY APPLICATION,2023-2031 (USD MILLION)
TABLE 356 ASIA PACIFIC: HUMAN ORGANOIDS MODELS MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 357 ASIA PACIFIC: HUMAN ORGANOID SERVICES MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 358 CHINA: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023-2031 (USD MILLION)
TABLE 359 CHINA: HUMAN ORGANOIDS MODELS MARKET, BY TYPE,2023-2031 (USD MILLION)
TABLE 360 CHINA: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE,2023-2031 (USD MILLION)
TABLE 361 CHINA: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE,2023-2031 (USD MILLION)
TABLE 362 CHINA: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE,2023-2031 (USD MILLION)
TABLE 363 CHINA: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE,2023-2031 (USD MILLION)
TABLE 364 CHINA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,2023-2031 (USD MILLION)
TABLE 365 CHINA: HUMAN ORGANOIDS MARKET, BY APPLICATION,2023-2031 (USD MILLION)
TABLE 366 CHINA: HUMAN ORGANOIDS MODELS MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 367 CHINA: HUMAN ORGANOID SERVICES MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 368 JAPAN: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023-2031 (USD MILLION)
TABLE 369 JAPAN: HUMAN ORGANOIDS MODELS MARKET, BY TYPE,2023-2031 (USD MILLION)
TABLE 370 JAPAN: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE,2023-2031 (USD MILLION)
TABLE 371 JAPAN: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE,2023-2031 (USD MILLION)
TABLE 372 JAPAN: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE,2023-2031 (USD MILLION)
TABLE 373 JAPAN: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE,2023-2031 (USD MILLION)
TABLE 374 JAPAN: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,2023-2031 (USD MILLION)
TABLE 375 JAPAN: HUMAN ORGANOIDS MARKET, BY APPLICATION,2023-2031 (USD MILLION)
TABLE 376 JAPAN: HUMAN ORGANOIDS MODELS MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 377 JAPAN: HUMAN ORGANOID SERVICES MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 378 INDIA: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023-2031 (USD MILLION)
TABLE 379 INDIA: HUMAN ORGANOIDS MODELS MARKET, BY TYPE,2023-2031 (USD MILLION)
TABLE 380 INDIA: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE,2023-2031 (USD MILLION)
TABLE 381 INDIA: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE,2023-2031 (USD MILLION)
TABLE 382 INDIA: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE,2023-2031 (USD MILLION)
TABLE 383 INDIA: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE,2023-2031 (USD MILLION)
TABLE 384 INDIA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,2023-2031 (USD MILLION)
TABLE 385 INDIA: HUMAN ORGANOIDS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
TABLE 386 INDIA: HUMAN ORGANOIDS MODELS MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 387 INDIA: HUMAN ORGANOID SERVICES MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 388 SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY OFFERING,2023-2031 (USD MILLION)
TABLE 389 SOUTH KOREA: HUMAN ORGANOIDS MODELS MARKET, BY TYPE,2023-2031 (USD MILLION)
TABLE 390 SOUTH KOREA: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE,2023-2031 (USD MILLION)
TABLE 391 SOUTH KOREA: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE,2023-2031 (USD MILLION)
TABLE 392 SOUTH KOREA: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE,2023-2031 (USD MILLION)
TABLE 393 SOUTH KOREA: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE,2023-2031 (USD MILLION)
TABLE 394 SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,2023-2031 (USD MILLION)
TABLE 395 SOUTH KOREA: HUMAN ORGANOIDS MARKET, BY APPLICATION,2023-2031 (USD MILLION)
TABLE 396 SOUTH KOREA: HUMAN ORGANOIDS MODELS MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 397 SOUTH KOREA: HUMAN ORGANOID SERVICES MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 398 AUSTRALIA: HUMAN ORGANOIDS MARKET, BY OFFERING,2023-2031 (USD MILLION)
TABLE 399 AUSTRALIA: HUMAN ORGANOIDS MODELS MARKET, BY TYPE,2023-2031 (USD MILLION)
TABLE 400 AUSTRALIA: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE,2023-2031 (USD MILLION)
TABLE 401 AUSTRALIA: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE,2023-2031 (USD MILLION)
TABLE 402 AUSTRALIA: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE,2023-2031 (USD MILLION)
TABLE 403 AUSTRALIA: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE,2023-2031 (USD MILLION)
TABLE 404 AUSTRALIA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,2023-2031 (USD MILLION)
TABLE 405 AUSTRALIA: HUMAN ORGANOIDS MARKET, BY APPLICATION,2023-2031 (USD MILLION)
TABLE 406 AUSTRALIA: HUMAN ORGANOIDS MODELS MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 407 AUSTRALIA: HUMAN ORGANOID SERVICES MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 408 REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY OFFERING,2023-2031 (USD MILLION)
TABLE 409 REST OF ASIA PACIFIC: HUMAN ORGANOIDS MODELS MARKET, BY TYPE,2023-2031 (USD MILLION)
TABLE 410 REST OF ASIA PACIFIC: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE, 2023-2031 (USD MILLION)
TABLE 411 REST OF ASIA PACIFIC: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE, 2023-2031 (USD MILLION)
TABLE 412 REST OF ASIA PACIFIC: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE, 2023-2031 (USD MILLION)
TABLE 413 REST OF ASIA PACIFIC: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE, 2023-2031 (USD MILLION)
TABLE 414 REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,2023-2031 (USD MILLION)
TABLE 415 REST OF ASIA PACIFIC: HUMAN ORGANOIDS MARKET, BY APPLICATION,2023-2031 (USD MILLION)
TABLE 416 REST OF ASIA PACIFIC: HUMAN ORGANOIDS MODELS MARKET, BY END USER, 2023-2031 (USD MILLION)
TABLE 417 REST OF ASIA PACIFIC: HUMAN ORGANOID SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
TABLE 418 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY COUNTRY,2023-2031 (USD MILLION)
TABLE 419 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY OFFERING,2023-2031 (USD MILLION)
TABLE 420 LATIN AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY TYPE,2023-2031 (USD MILLION)
TABLE 421 LATIN AMERICA: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE, 2023-2031 (USD MILLION)
TABLE 422 LATIN AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE,2023-2031 (USD MILLION)
TABLE 423 LATIN AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE, 2023-2031 (USD MILLION)
TABLE 424 LATIN AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE,2023-2031 (USD MILLION)
TABLE 425 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,2023-2031 (USD MILLION)
TABLE 426 LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY APPLICATION,2023-2031 (USD MILLION)
TABLE 427 LATIN AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 428 LATIN AMERICA: HUMAN ORGANOID SERVICES MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 429 BRAZIL: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023-2031 (USD MILLION)
TABLE 430 BRAZIL: HUMAN ORGANOIDS MODELS MARKET, BY TYPE,2023-2031 (USD MILLION)
TABLE 431 BRAZIL: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE,2023-2031 (USD MILLION)
TABLE 432 BRAZIL: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE,2023-2031 (USD MILLION)
TABLE 433 BRAZIL: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE,2023-2031 (USD MILLION)
TABLE 434 BRAZIL: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE,2023-2031 (USD MILLION)
TABLE 435 BRAZIL: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,2023-2031 (USD MILLION)
TABLE 436 BRAZIL: HUMAN ORGANOIDS MARKET, BY APPLICATION,2023-2031 (USD MILLION)
TABLE 437 BRAZIL: HUMAN ORGANOIDS MODELS MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 438 BRAZIL: HUMAN ORGANOID SERVICES MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 439 MEXICO: HUMAN ORGANOIDS MARKET, BY OFFERING, 2023-2031 (USD MILLION)
TABLE 440 MEXICO: HUMAN ORGANOIDS MODELS MARKET, BY TYPE,2023-2031 (USD MILLION)
TABLE 441 MEXICO: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE,2023-2031 (USD MILLION)
TABLE 442 MEXICO: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE,2023-2031 (USD MILLION)
TABLE 443 MEXICO: HUMAN ORGANOIDS MODELS MARKET, BY CULTURE TYPE,2023-2031 (USD MILLION)
TABLE 444 MEXICO: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE,2023-2031 (USD MILLION)
TABLE 445 MEXICO: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,2023-2031 (USD MILLION)
TABLE 446 MEXICO: HUMAN ORGANOIDS MARKET, BY APPLICATION,2023-2031 (USD MILLION)
TABLE 447 MEXICO: HUMAN ORGANOIDS MODELS MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 448 MEXICO: HUMAN ORGANOID SERVICES MARKET, BY END USER,2023-2031 (USD MILLION)
TABLE 449 REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY OFFERING,2023-2031 (USD MILLION)
TABLE 450 REST OF LATIN AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY TYPE,2023-2031 (USD MILLION)
TABLE 451 REST OF LATIN AMERICA: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE, 2023-2031 (USD MILLION)
TABLE 452 REST OF LATIN AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE, 2023-2031 (USD MILLION)
TABLE 453 REST OF LATIN AMERICA: HUMAN ORGANOIDS MODELS MARKET,BY CULTURE TYPE, 2023-2031 (USD MILLION)
TABLE 454 REST OF LATIN AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE, 2023-2031 (USD MILLION)
TABLE 455 REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,2023-2031 (USD MILLION)
TABLE 456 REST OF LATIN AMERICA: HUMAN ORGANOIDS MARKET, BY APPLICATION,2023-2031 (USD MILLION)
TABLE 457 REST OF LATIN AMERICA: HUMAN ORGANOIDS MODELS MARKET, BY END USER, 2023-2031 (USD MILLION)
TABLE 458 REST OF LATIN AMERICA: HUMAN ORGANOID SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
TABLE 459 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY OFFERING,2023-2031 (USD MILLION)
TABLE 460 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MODELS MARKET, BY TYPE,2023-2031 (USD MILLION)
TABLE 461 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS SERVICES MARKET, BY SERVICE TYPE, 2023-2031 (USD MILLION)
TABLE 462 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MODELS MARKET, BY MODEL TYPE, 2023-2031 (USD MILLION)
TABLE 463 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MODELS MARKET,BY CULTURE TYPE, 2023-2031 (USD MILLION)
TABLE 464 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MODELS MARKET, BY SOURCE, 2023-2031 (USD MILLION)
TABLE 465 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY DISEASE AREA,2023-2031 (USD MILLION)
TABLE 466 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MARKET, BY APPLICATION,2023-2031 (USD MILLION)
TABLE 467 MIDDLE EAST & AFRICA: HUMAN ORGANOIDS MODELS MARKET, BY END USER, 2023-2031 (USD MILLION)
TABLE 468 MIDDLE EAST & AFRICA: HUMAN ORGANOID SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
TABLE 469 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS INHUMAN ORGANOIDS MARKET
TABLE 470 HUMAN ORGANOIDS MARKET: DEGREE OF COMPETITION
TABLE 471 HUMAN ORGANOIDS MARKET: REGION FOOTPRINT
TABLE 472 HUMAN ORGANOIDS MARKET: OFFERING FOOTPRINT
TABLE 473 HUMAN ORGANOIDS MARKET: SOURCE FOOTPRINT
TABLE 474 HUMAN ORGANOIDS MARKET: APPLICATION FOOTPRINT
TABLE 475 HUMAN ORGANOIDS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 476 HUMAN ORGANOIDS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
TABLE 477 HUMAN ORGANOIDS MARKET: PRODUCT/SERVICE LAUNCHES,JANUARY 2023-SEPTEMBER 2026
TABLE 478 HUMAN ORGANOIDS MARKET: DEALS, JANUARY 2023-SEPTEMBER 2026
TABLE 479 HUMAN ORGANOIDS MARKET: OTHER DEVELOPMENTS,JANUARY 2023-SEPTEMBER 2026
TABLE 480 MERCK: COMPANY OVERVIEW
TABLE 481 MERCK: PRODUCTS/SERVICES OFFERED
TABLE 482 MERCK: DEALS, JANUARY 2023-SEPTEMBER 2026
TABLE 483 MERCK: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
TABLE 484 DANAHER CORPORATION: COMPANY OVERVIEW
TABLE 485 DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED
TABLE 486 DANAHER CORPORATION: OTHER DEVELOPMENTS,JANUARY 2023-SEPTEMBER 2026
TABLE 487 SAMSUNG BIOLOGICS: COMPANY OVERVIEW
TABLE 488 SAMSUNG BIOLOGICS: PRODUCTS/SERVICES OFFERED
TABLE 489 SAMSUNG BIOLOGICS: SERVICE LAUNCHES, JANUARY 2023-SEPTEMBER 2026
TABLE 490 WUXI APPTEC: COMPANY OVERVIEW
TABLE 491 WUXI APPTEC: PRODUCTS/SERVICES OFFERED
TABLE 492 WUXI APPTEC: OTHER DEVELOPMENTS, JANUARY 2023-SEPTEMBER 2026
TABLE 493 EVOTEC SE: COMPANY OVERVIEW
TABLE 494 EVOTEC SE: PRODUCTS/SERVICES OFFERED
TABLE 495 EVOTEC SE: DEALS, JANUARY 2023-SEPTEMBER 2026
TABLE 496 CHAMPIONS ONCOLOGY: COMPANY OVERVIEW
TABLE 497 CHAMPIONS ONCOLOGY: PRODUCTS/SERVICES OFFERED
TABLE 498 CHAMPIONS ONCOLOGY: OTHER DEVELOPMENTS,JANUARY 2023-SEPTEMBER 2026
TABLE 499 ACROBIOSYSTEMS: COMPANY OVERVIEW
TABLE 500 ACROBIOSYSTEMS: PRODUCTS/SERVICES OFFERED
TABLE 501 BIOMORGAN: COMPANY OVERVIEW
TABLE 502 BIOMORGAN: PRODUCTS/SERVICES OFFERED
TABLE 503 BIOMORGAN: DEALS, JANUARY 2023-SEPTEMBER 2026
TABLE 504 ORGANOID SCIENCES, INC.: COMPANY OVERVIEW
TABLE 505 ORGANOID SCIENCES, INC.: PRODUCTS/SERVICES OFFERED
TABLE 506 ORGANOID SCIENCES, INC.: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
TABLE 507 ORGANOID SCIENCES, INC.: OTHER DEVELOPMENTS,JANUARY 2023-SEPTEMBER 2026
TABLE 508 JSR CORPORATION: COMPANY OVERVIEW
TABLE 509 JSR CORPORATION: PRODUCTS/SERVICES OFFERED
TABLE 510 JSR CORPORATION: DEALS, JANUARY 2023-SEPTEMBER 2026
TABLE 511 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW
TABLE 512 THERMO FISHER SCIENTIFIC: PRODUCTS/SERVICES OFFERED
TABLE 513 THERMO FISHER SCIENTIFIC: PRODUCT LAUNCHES,JANUARY 2023-SEPTEMBER 2026
TABLE 514 THERMO FISHER SCIENTIFIC: DEALS, JANUARY 2023-SEPTEMBER 2026
TABLE 515 BRUKER CORPORATION: COMPANY OVERVIEW
TABLE 516 BRUKER CORPORATION: PRODUCTS/SERVICES OFFERED
TABLE 517 BRUKER CORPORATION: PRODUCT & SERVICE LAUNCHES,JANUARY 2023-SEPTEMBER 2026
TABLE 518 BRUKER CORPORATION: DEALS, JANUARY 2023-SEPTEMBER 2026
TABLE 519 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
TABLE 520 CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES OFFERED
TABLE 521 PHARMARON: COMPANY OVERVIEW
TABLE 522 PHARMARON: PRODUCTS/SERVICES OFFERED
TABLE 523 VIVOSIM LABS, INC.: COMPANY OVERVIEW
TABLE 524 VIVOSIM LABS, INC.: PRODUCTS/SERVICES OFFERED
TABLE 525 VIVOSIM LABS, INC.: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
TABLE 526 VIVOSIM LABS, INC.: DEALS, JANUARY 2023-SEPTEMBER 2026
TABLE 527 STEMCELL TECHNOLOGIES: COMPANY OVERVIEW
TABLE 528 STEMCELL TECHNOLOGIES: PRODUCTS/SERVICES OFFERED
TABLE 529 STEMCELL TECHNOLOGIES: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
TABLE 530 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
TABLE 531 RISK ASSESSMENT: HUMAN ORGANOIDS MARKET
LIST OF FIGURES
FIGURE 1 HUMAN ORGANOIDS MARKET SEGMENTATION
FIGURE 2 HUMAN ORGANOIDS MARKET: YEARS CONSIDERED
FIGURE 3 MARKET SCENARIO
FIGURE 4 GLOBAL HUMAN ORGANOID MODELS MARKET, 2023-2031
FIGURE 5 GLOBAL HUMAN ORGANOID SERVICES MARKET, 2023-2031
FIGURE 6 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN HUMAN ORGANOIDS MARKET, 2023-2026
FIGURE 7 DISRUPTIONS INFLUENCING GROWTH OF HUMAN ORGANOIDS MARKET
FIGURE 8 HIGH-GROWTH SEGMENTS IN HUMAN ORGANOIDS MARKET, 2026-2031
FIGURE 9 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN HUMAN ORGANOID MODELS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 10 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN HUMAN ORGANOID SERVICES MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 11 INCREASING ADOPTION OF HUMAN ORGANOID MODELS IN DRUG DISCOVERY TO PROPEL THE HUMAN ORGANOIDS MARKET
FIGURE 12 US AND SERVICES ACCOUNTED FOR LARGEST SHARE OF THE HUMAN ORGANOIDS MARKET IN NORTH AMERICA IN 2025
FIGURE 13 ASIA PACIFIC LIKELY TO BE FASTEST-GROWING REGION DURING FORECAST PERIOD
FIGURE 14 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 15 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 16 HUMAN ORGANOIDS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,AND CHALLENGES
FIGURE 17 GLOBAL HUMAN ORGANOIDS MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 18 GLOBAL HUMAN ORGANOID MODELS MARKET: VALUE CHAIN ANALYSIS
FIGURE 19 GLOBAL HUMAN ORGANOIDS SERVICES MARKET: VALUE CHAIN ANALYSIS
FIGURE 20 GLOBAL HUMAN ORGANOIDS MARKET: ECOSYSTEM ANALYSIS
FIGURE 21 HUMAN ORGANOIDS MARKET: TRENDS/DISRUPTIONS IMPACTINGCUSTOMER BUSINESS
FIGURE 22 TOP APPLICANTS & OWNERS (COMPANIES) FOR HUMAN ORGANOIDS PATENTS, 2015-DECEMBER 2025
FIGURE 23 IMPACT OF AI/GEN AI ON THE GLOBAL HUMAN ORGANOIDS MARKET
FIGURE 24 ILLUSTRATIVE STAKEHOLDER INFLUENCE, BY OFFERING
FIGURE 25 ILLUSTRATIVE BUYING PRIORITIES, BY END USER
FIGURE 26 NORTH AMERICA: HUMAN ORGANOIDS MARKET SNAPSHOT
FIGURE 27 ASIA PACIFIC: HUMAN ORGANOIDS MARKET SNAPSHOT
FIGURE 28 REVENUE ANALYSIS OF KEY PLAYERS IN HUMAN ORGANOIDS MARKET(2023-2025)
FIGURE 29 MARKET SHARE ANALYSIS OF KEY PLAYERS IN HUMAN ORGANOIDS MARKET (2025)
FIGURE 30 HUMAN ORGANOIDS MARKET: COMPANY EVALUATION MATRIX(KEY PLAYERS), 2025
FIGURE 31 HUMAN ORGANOIDS MARKET: COMPANY FOOTPRINT
FIGURE 32 HUMAN ORGANOIDS MARKET: COMPANY EVALUATION MATRIX(STARTUPS/SMES), 2025
FIGURE 33 EV/EBITDA OF KEY VENDORS
FIGURE 34 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 35 HUMAN ORGANOIDS MARKET: BRAND COMPARISON
FIGURE 36 MERCK: COMPANY SNAPSHOT
FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT
FIGURE 38 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT
FIGURE 39 WUXI APPTEC: COMPANY SNAPSHOT
FIGURE 40 EVOTEC SE: COMPANY SNAPSHOT
FIGURE 41 ACROBIOSYSTEMS: COMPANY SNAPSHOT
FIGURE 42 ORGANOID SCIENCES, INC.: COMPANY SNAPSHOT
FIGURE 43 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
FIGURE 44 BRUKER CORPORATION: COMPANY SNAPSHOT
FIGURE 45 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
FIGURE 46 PHARMARON: COMPANY SNAPSHOT
FIGURE 47 HUMAN ORGANOIDS MARKET: RESEARCH DESIGN METHODOLOGY
FIGURE 48 HUMAN OGRANOIDS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
FIGURE 49 GLOBAL HUMAN ORGANOIDS MARKET ESTIMATION, 2025
FIGURE 50 HUMAN ORGANOIDS MARKET: COMPANY REVENUE ANALYSIS(BOTTOM-UP APPROACH) (2025)
FIGURE 51 HUMAN ORGANOIDS MARKET: INSIGHTS FROM PRIMARIES
FIGURE 52 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
FIGURE 53 HUMAN ORGANOIDS MARKET: CAGR PROJECTIONS
FIGURE 54 DATA TRIANGULATION METHODOLOGY

Table Information